Drug interactions
Indacaterol-glycopyrronium + Quizartinib
Severity: Major
Indacaterol-glycopyrronium and Quizartinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Quizartinib causes dose-dependent QT prolongation with a risk of torsades de pointes. Indacaterol, a long-acting beta-agonist, may add to QTc prolongation and can lower potassium, increasing arrhythmic risk.
What this interaction means in plain words
Indacaterol-glycopyrronium and Quizartinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Indacaterol-glycopyrronium belongs to Respiratory; Quizartinib belongs to Oncology.
Why it happens
Additive prolongation of cardiac repolarization, with beta-agonist-induced hypokalemia as a possible aggravating factor.
What to do
Perform ECG monitoring more often than usual and keep potassium and magnesium within normal limits. Reduce or interrupt quizartinib if the QTc rises significantly, and consider non-QT-prolonging bronchodilator options.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Indacaterol-glycopyrronium and Quizartinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Other interactions of Quizartinib
- Quizartinib + Thioridazine Contraindicated
- Quizartinib + Ziprasidone Contraindicated
- Alfuzosin + Quizartinib Major
- Amiodarone + Quizartinib Major
- Amitriptyline + Quizartinib Major
- Amobarbital + Quizartinib Major
Frequently asked questions
Can I take Indacaterol-glycopyrronium with Quizartinib?
MediHelp rates the interaction as major. Indacaterol-glycopyrronium and Quizartinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Quizartinib causes dose-dependent QT prolongation with a risk of torsades de pointes. Indacaterol, a long-acting beta-agonist, may add to QTc prolongation and can lower potassium, increasing arrhythmic risk.
How serious is the interaction between Indacaterol-glycopyrronium and Quizartinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Perform ECG monitoring more often than usual and keep potassium and magnesium within normal limits. Reduce or interrupt quizartinib if the QTc rises significantly, and consider non-QT-prolonging bronchodilator options.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
